Twenty years of metallo-neurobiology: where to now?
The redox active transition metals Cu2+ and Fe3+ have been proposed as important factors in the neuropathology of Alzheimer's disease (AD) and other neurodegenerative diseases. The field that has been called metallo-neurobiology has expanded greatly in the last 20 years. Although there is much experimental evidence on various aspects of the interaction between these metals and the molecular and supramolecular components of the neuropil and the structural biology of metal binding, we are far from fully understanding the part this interaction plays in the normal CNS and in neurodegeneration. This understanding is needed if we are to move beyond the promising, but semi-empirical, approaches to therapies of these diseases based on metal attenuation.
Bush
Ashley I
AI
Oxidation Disorders Laboratory, Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, VIC 3052, Australia.
Curtain
Cyril C
CC
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002490:Central Nervous System / Q000473:pathology / Q000502:physiology / Q000503:physiopathology; D003300:Copper / Q000378:metabolism / Q000627:therapeutic use; D005290:Ferric Compounds / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009446:Neurobiology / Q000639:trends*; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects
D000975:Antioxidants; D005290:Ferric Compounds; D003300:Copper